Discussion
Earlier studies on the value of fenfluramine as an appetitedepressant were encouraging. Traherne (1965) reported a mean weight loss of 7.0 lb. (3,175 g.) in patients taking fenfluramine for 12 weeks, compared with a loss of 2.3 lb. (1,040 g.) in those given placebo tablets; Duncan et al. (1965) found that patients given fenfluramine for four weeks, lost, on average, 8.9 lb. (4,040 g.), whereas those taking a placebo lost 4.4 lb. (1,995 g.) .
In both studies, however, patients were instructed in a lowcalorie diet at the start of the study, which makes it difficult to assess the effect of the drug.
The present investigation was carried out on patients with "refractory obesity." Such subjects provide a severe test for an appetite-depressant, but one which is valuable because they form a fairly standard group and are also those most in need of an effective aid to dieting. In an attempt to eliminate the influence of dietary change the patients were asked to make no deliberate alteration in their dietary habits ; that this was effective is suggested by the poor response of those taking the inert tablets.
The mean weight loss of 9.3 lb. (4,220 g.) in 12 weeks which occurred in the patients taking the fenfluramine is greater than that obtained in trials of comparable duration in similar patients having refractory obesity using phenmetrazine (Duncan et al., 1960) , diethylpropion (Seaton et al., 1961) , chlorphentermine (Seaton et al., 1964a) , and dexamphetamine and phentermine (Seaton et al., 1964b) , in which the mean weight loss varied from 2.6 lb. (1,180 g.) with diethylpropion to 6.3 lb. (2,860 g.) with dexamphetamine. Moreover, whereas all the above preparations had clearly lost their appetite-suppressant effect in the majority of patients within 12 weeks, no such tolerance to the drug was demonstrated with fenfluramine. However, a longer study than that reported here would be required to demonstrate if and when fenfluramine loses its appetitedepressant effect. Thus fenfluramine, although expensive, appears to be a more effective appetite-suppressant than the other anorectic drugs that we have so far tested.
However, a mean weight loss of only 9.3 lb. (4,220 g.) in 12 weeks is still not very substantial, though it does represent a mean reduction in food intake of about 300 calories a day from that which would have kept the patient's weight steady.
Side-effects were not particularly troublesome, although diarrhoea occurred in 10 of the 25 patients taking fenfluramine, being severe in two. Evidence of C.N.S. stimulation was not obtained in the present study, and the drug has previously been shown to have no hypertensive action (Le Douarec and Schmitt, 1964; Lambusier, 1965 ).
Summary
The appetite-depressant action of fenfluramine was evaluated against an inert tablet by a 12-weeks double-blind trial in 60 women having " refractory obesity "; 50 patients completed the trial. The mean weight change after 12 weeks was -9.3 lb. (-4,220 g.) in those taking fenfluramine, whereas in those given dummy tablets it was +0.4 lb. (+0.180 g.).
Side , 1966, 2, 625-627 Methisazone (N-methylisatin 3-thiosemicarbazone, 33T57, Marboran) has been shown to be effective in vitro against pox viruses (Sheffield et al., 1960) and adenoviruses (Bauer, personal communication, 1966) . In human trials it acts as a prophylactic against smallpox infection in contacts (Bauer et al., 1963) and inhibits the effects of vaccination (Landsman and Grist, 1964) . As treatment for the established condition it has been reported to be successful in eczema vaccinatum (Turner et al., 1962) , generalized vaccinia (Davidson and Hayhoe, 1962) , and vaccinia gangrenosa (Daly and Jackson, 1962) . It was unsuccessful in Marsden's (1962) case of smallpox and another case of vaccinia (Connolly et al., 1962) .
Two of the successfully treated patients (Daly and Jackson, 1962; Davidson and Hayhoe, 1962) became ill after vaccination while taking prednisolone for a follicular lymphoma and acute leukaemia respectively. No mention is made in either report of the effect of the compound on the underlying disorder, but in the latter, from the figures given, the patient's haematological state seemed to improve in spite of reduction in steroid and cytotoxic medication. Since it seemed possible that this had occurred as a result of the inhibition of a postulated tumour virus, a trial of methisazone in malignant disease was suggested.
CASE MATERIAL Seven patients with an initial diagnosis of advanced reticulosis were admitted to the trial. It was felt that conventional therapy alone would not result in lasting benefit. Two had Hodgkin's granuloma (Jackson and Parker, 1944) , two had follicular lymphoma types ii and iii (Rappaport et al., 1956) , one had lymphocytic lymphosarcoma, and one had acute myeloid leukaemia. One case, originally reported to be a malignant lymphoma, probably follicular lymphoma, had this diagnosis withdrawn on review of the material. This was requested because there was no confirmation of the diagnosis on lymphangiography and no response to x-ray therapy. He 
Case 2 received only prednisolone and antibiotics, and Case 5 had x-ray therapy to the upper abdomen to a tumour dose of 2,500 rads before the diagnosis was called into question.
RESULTS
The clinical observations are summarized in Table I . Two deaths occurred during treatment and two later. None could be attributed to the compound under trial.
Effect on Malignancy.-Methisazone alone had no effect on lymph nodes except in Case 7, and this was only temporary. When it was combined with cyclophosphamide in intensive dosage no patient failed to show some response, and even in Case 4, where only oral medication was given, there was little evidence of disease six weeks after the start of treatment. Cyclophosphamide had lost its effect in Cases 1 and 4 in previous courses. The tumour seemed to recover some sensitivity to the drug, if only for a short period. In the leukaemic patient there was an initial improvement in haemoglobin, W.B.C., and platelets, which had all remained at low levels for some weeks in spite of steroids, antimetabolites, and cytotoxics. This was, however, accompanied by an increasing proportion of blasts in the peripheral blood.
Effect on Fever.-All cases except Case 1 had a fever at the start of treatment. One patient (Case 3) died four days after starting treatment without any real alteration in the temperature chart, but all the others, including the non-malignant Case 5, showed a fairly constant reduction in the level to normal or close to normal during the first one or two courses of methisazone (Fig. 2) . Antibiotics had been used in Cases 2, 3, 4, 5, and 6 without effect. A change of antibiotic in Case 2, and possibly Case 4, may have influenced the initial fall in temperature, and these two did have intercurrent infections just before entering the trial. However, it is noteworthy that further fever occurred in both patients in the rest periods between courses. Antipyretics were not administered.
Effect on the Liver.-The liver diminished in size in three cases, and in all except one the hepatic-function tests improved.
A ward-test finding of bile in the urine led to the interruption of the third course of methisazone on the third day in Case 7, but subsequent biochemical and serological estimations failed to confirm this. Owing to obstructive jaundice from the nodes around the porta hepatis Case 3 excreted bile throughout his treatment. There was no evidence of liver damage due to the test compound except possibly in Case 1, in whom an elevated transaminase rose slightly during treatment. This later returned to normal.
Effect on Serum Globulins.-The most striking evidence of response was in the electrophoretic pattern of the serum of Case 7, in whom a grossly increased alpha-2 globulin of 1.7 g./100 ml. returned to normal levels over the two weeks of treatment with methisazone alone (Table II) . The abnormal amount of protein had appeared during the two years' observation prior to methisazone administration, and was not decreased by x-ray therapy to the abdominal nodes. In Cases 2 and 6 a similar return to normal of abnormal amounts of alpha-globulin was noted.
Further Treatment.-Case 6 wleas given a course of Vincaleukoblastine (V.L.B.) three months after treatment, but this was curtailed by a falling blood count. Her remission with this was also quite short, and death occurred two months later. Cases 1 and 7 were undergoing x-ray therapy to residual nodes in an attempt to eradicate all clinical evidence of disease; Case 5 was still under investigation at another hospital.
Side-efJects.-In three cases (Nos. 2, 3, and 5) vomiting occurred, but all were severely ill. Others complained of nausea, but this may have been related to the violent yellow colour of the mixture or the sickly sweetness of the suspending vehicle.
Toxicity.-Case 6 developed weakness and a coarse tremor of both hands with fasciculation of the tongue and muscles of the upper limb in the first day of the third course of methi- sazone, 12 days after the beginning of treatment. During the second course, however, she also was given three daily intravenous doses of cyclophosphamide, 500 mg., which produced a marked marrow-depression. Whether the motor-neurone disease was related to methisazone or cyclophosphamide is unknown, but the latter would be more likely on the time-relationships and the sensitivity shown by the patient. No sensory impairment was found, and symptoms and signs cleared within three months. Peripheral blood counts were carried out at frequent intervals during administration and did not deteriorate during treatment with methisazone alone. If anything, there was a tendency for improvement, but this may have been due to recovery from previous cytotoxic or x-ray therapy.
DISCUSSION
The results reported here suggest antineoplastic activity, in some cases of lymphoma, of an agent known to be effective against pox viruses (Bauer et al., 1963) and adenoviruses (Bauer, personal communication, 1966) . No conclusions cats 'e drawn as yet, but the unexpected benefit obtained seemed to warrant publication. This benefit was probably not due to the abolition of an intermittent infection, as the neutrophil alkaline phosphatase score in Case 7 was only 42. SUMMARY A pilot trial is reported of methisazone, a compound effective in vitro and in vivo against pox viruses and adenoviruses, in six patients with advanced malignant lymphoma and in one in whom this diagnosis was withdrawn at a later date. Objective evidence of a temporary beneficial effect was found in the temperature charts, liver-function tests, and the electrophoretic patterns of the serum. One patient died without effective dosage being achieved, one died of steroid-induced hyperglycacmia, and two died four and five months after treatment, having had temporary remissions. Two patients remain alive and relatively well, although they are receiving local x-ray therapy for residual lymph-node enlargement. All those who survived more than one month were given cyclophosphamide in addition to the anti-viral agent, but the beneficial effects reported were noted before the introduction of such therapy. Possible neurotoxic cffects were seen in one case. Extension of the trial, possibly with variation in the dosage schedule, is intended. 
